Loracarbef (200 mg) CAS: 121961-22-6 Supplier Information and Product Details

Loracarbef is a new orally active broad-spectrum cephalosporin suitable for twice-a-day dosing. It is approved for use in both ***s and children for the treatment of upper and lower respiratory tract infections, urinary tract infections, and skin infections. The drug was originally developed by Kyowa Hakko in Japan and is marketed under the brand name Lorabid.

Frequently Asked Questions

Q: What is the main use of Loracarbef?

A: Loracarbef is primarily used as an antibiotic for treating various bacterial infections, including respiratory tract infections, urinary tract infections, and skin infections in both ***s and children.

Q: How is Loracarbef administered?

A: Loracarbef is typically administered orally, with a dosing schedule of twice a day due to its broad-spectrum cephalosporin properties.

Q: Is Loracarbef approved by regulatory agencies?

A: Yes, Loracarbef has been approved for use in both ***s and children. Some suppliers mention FDA, GMP, and CEP approvals for their manufacturing processes.

Q: What is the significance of the monohydrate form of Loracarbef?

A: The monohydrate form of Loracarbef (C16H16ClN3O4 · H2O) is the standard formulation of the drug. This form may contribute to its stability and solubility characteristics.